6 Undervalued Biotechnology Stocks for Friday, November 01
Discover the top 6 undervalued Biotechnology stocks for Friday, November 01 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.
Commentary & Analysis
Is Azitra Inc (AZTR) Stock a Good Investment?
Learn more about Azitra Inc's (AZTR) stock grades for Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Pratham Shah
Financial Summary
| Share Statistics | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.1 | $252.6 | 1% |
|
| Shares Out (Mil) | 15.5 | 52.3 | 26% |
|
| Institutional Ownership | 62.6% | 92.1% | 40% |
|
| Float (Mil) | 12.1 | 40.2 | 22% |
|
| Beta | -1.28 | 0.95 | 1% |
|
| Avg Daily Volume (000s) | 640 | 455 | 63% |
|
| Price Change (52-week) |
(89.3%) | 52.9% | 4% |
|
| Growth | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (10.1%) | (9.9%) | 29% |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($43) | 28% |
|
| EPS (TTM) | ($1.431) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $5 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 10% |
|
| Enterprise Value (Q1) (Mil) | ($6) | $180 | 2% |
|
| Valuation | AZTR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.20 | 2.56 | 3% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AZTR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (131.0%) | (49.8%) | 4% |
|
| ROE | (158.7%) | (55.5%) | 6% |
|
| Liabilities to Assets | 13.6% | 30.3% | 8% |
|
| F-Score | 4 | 3 | 34% |
|
Azitra, Inc. did not pass any screens on 7/31/2026.
